Halyard Health (HYH) Misses Q4 EPS by 23c, Offers FY17 Guidaance

Halyard Health (NYSE: HYH) reported Q4 EPS of $0.21, $0.23 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $410 million versus the consensus estimate of $401.72 million.

2017 Outlook and Key Planning Assumptions

Based on current trends, the company expects 2017 net sales, on a constant currency basis, to be even to up 2 percent compared to 2016, which includes the impact from CORPAK. Adjusted earnings per diluted share are anticipated to be in the range of $1.70 to $2.00 for the full-year.

(Street sees FY17 EPS of $1.90 on revenue of $1.58 billion).

For earnings history and earnings-related data on Halyard Health (HYH) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation